The mechanisms and antinociceptive effects of a novel α 2A adrenoceptor agonist, 3-(2-chloro-6-fluorobenzil)-imidazolinide-2,4-dione (PT-31) were investigated using animal models of acute and chronic pain. The effects of PT-31 on pain responses were examined using hot plate and formalin tests in mice and spinal nerve ligation (SNL)-induced hyperalgesia in rats. The effects of antagonists acting on α adrenoceptor were assessed to investigate the interaction of these pathways upon PT-31 induced antinociception. PT-31 effects on motor activity/ skills and on hemodynamic parameters were also evaluated. PT-31 had dose-dependent antinociception effects on hot-plate and formalin-injection induced pain responses. Thermal hyperalgesia and mechanical allodynia were reduced following a 7 d treatment with PT-31 (1, 5, and 10 mg/kg/d, p.o.), and those effects were attenuated by yohimbine (5 mg/kg), atropine (2 mg/kg), L-nitro arginine methyl ester (L-NAME; 30 mg/kg), or naloxone (2 mg/kg). In contrast to clonidine, PT-31 did not have locomotor or hemodynamic effects in rats. The present results suggest that PT-31 represents a candidate for pain treatment with advantages over clonidine, namely no locomotor or hemodynamic impairments.
Introduction
Chronic neuropathic pain, which has prevalence of 17-47% on the general population worldwide, has a negative impact on quality of life and generates high health-care costs (Torrance et al., 2013; Toth et al., 2009) . Neuropathic pain is a multifactorial disease and responses to existing treatments are often inadequate. Currently, neuropathic pain patients are treated with a single compound or a combination of compounds activating several targets simultaneously (Hahn et al., 2004; Kieburtz et al., 1998; Smith and Torrance, 2012) .
Opioid receptors are an important therapeutic target for pain (Boudreau et al., 2009; Dowell et al., 2016) . Morphine and tramadol which are agonists of µ-opioid receptor are still used efficaciously for analgesia (Norrbrink and Lundeberg, 2009) . A diversity of drugs with various targets-including the calcium channel α 2 δ ligand blocker, pregabalin (Dooley et al., 2002) , the μ-opioid receptor agonist and norepinephrine reuptake inhibitor tapentadol (Tzschentke et al., 2007) , the serotonin/norepinephrine reuptake inhibitor amitriptyline (Esser and Sawynok, 1999) , and local anesthetics (Baron et al., 2016; Dewulf and van Langenhove, 2002) are also used to support management of neuropathic pain. Although cholinergic targets have been implicated in pain control, there are no muscarinic or nicotinic cholinergic receptor agonists currently available for the treatment of neuropathic pain (Hayashida et al., 2006; Kesingland et al., 2000; Mendes et al., 2013) .
The α 2 adrenoceptors are widely distributed in the peripheral and central nervous systems (Daunt et al., 1997; Gilsbach and Hein, 2012) . Although both α 2A and α 2C are expressed in the spinal cord, the α 2A adrenoceptor has been related more strongly to pain relief. Clonidine, an archetypical α 2A adrenoceptor agonist, affects the nervous system on multiple levels in the spinal cord and brain when administered systemically. Secondary effects beyond pain relief including sedation and hypotension are significant concerns that limit systemic clonidine use (Kumar et al., 2014) .
Activation of α 2 adrenoceptors reduces pain transmission by reducing the release of pro-nociceptive transmitters, such as substance P and glutamate, from primary afferent terminals (Sonohata et al., 2004) , and by inducing hyperpolarization of ascending neurons in the dorsal horn (Kim et al., 2013) . Commonly, clonidine is co-administered as an adjuvant therapy together with opioid receptor agonists for chronic pain management.
Activation of α 2-adrenoceptors in the locus coeruleus can suppress noradrenergic neural activity, resulting in sedation and hypnosis (Funai et al., 2014; Zhang et al., 2015) , and also activate pain-modulating descending norepinephrine pathways in the spinal cord. Clonidine and dexmedetomidine are used often perioperatively and in the intensive care setting for sedation and analgesia (Kubre et al., 2016) . The main systemic side effect of these compounds especially clonidine, is hypotension which can occur with acute intravenous injection or prolonged treatment. Previously, it was demonstrated that 3-(2-cloro-6-fluorobenzil)-imidazolidine-2,4-dione (PT-31), a novel α 2A adrenoceptor agonist (Fig. 1A) , has antinociceptive profile and high affinity for the α 2 adrenoceptor. The antinociceptive activity of PT-31 was blocked after pretreatment with BRL 4408, a specific antagonist for the α 2A adrenoceptors but not with ARC 239, an antagonist for α 2B and α 2C adrenoceptors (Sudo et al., 2010) .
The aim of this study was to evaluate the antinociceptive effects of orally administered PT-31 in animal models of acute, inflammatory, and neuropathic pain. Additionally, we examined the possible mechanism of action of PT-31-mediated antinociceptive effects and tested whether PT-31 has advantages over clonidine with respect to locomotor and hemodynamic secondary effects.
Materials and methods

Drugs
PT-31 was provided by Núcleo de Pesquisa em Inovação Terapêutica da Universidade Federal de Pernambuco, Brazil (Sudo et al., 2010) . Morphine, dimethylsulphoxide (DMSO), naloxone, and clonidine were provided by Cristália Produtos Químicos e Farmacêuticos Ltda (São Paulo, SP, Brazil). Yohimbine, atropine, acetylsalicylic acid, formaldehyde, and L-nitro arginine methyl ester (L-NAME) were purchased from Sigma-Aldrich (St. Louis, MO, USA). All drugs were dissolved in saline, except PT-31, which was dissolved in a formulation composed of DMSO: saline (1:1).
Animals and housing conditions
The Institutional Animal Care and Use Committee (DFBCICB 017) approved all protocols for this study. Male Swiss mice (18-25 g) and male Wistar rats (180-220 g) were obtained from Institute of Biomedical Science at Federal University of Rio de Janeiro, Brazil and housed under a 12-h light/dark cycle at 21°C and 60% humidity with food and water ad libitum. The animals were randomly divided into control and treatment groups (n= 6-10).
Acute pain mouse model: hot plate test
Mice were placed on a hot plate (52°C, Letica 7406, Barcelona, Spain) (Eddy and Leimbach, 1953; Mendes et al., 2009) and their latency to exhibit a pain response (e.g., jumping, hind-paw licking, and/ or shaking) was observed with a 30-s cut-off (maximal time on the plate). Morphine (10 mg/kg), clonidine (0.4 mg/kg), vehicle, and PT-31 (10, 50, and 100 mg/kg) were administered orally by gavage. Latency was assessed 5, 15 and 30 min later and then every 10 min until nociception recovery was evidenced. The results are presented as percentage of maximum possible effect (%MPE) calculated by the following formula (Sudo et al., 2015) :
The highest %MPE noted in a time-course curve after compounds administration was selected to perform the graphic in the Fig. 1B. 
Inflammatory pain mouse model: formalin-induced hind paw-licking
Formalin-induced neurogenic and inflammatory pain (Abbott et al., 1995; Sudo et al., 2015) was induced by injecting formalin (2.5%, 20 µl) into the right hind paw 15 min after single oral administration by gavage of vehicle, acetylsalicylic acid (150 mg/kg), clonidine (0.4 mg/ kg), or PT-31 (10, 50, and 100 mg/kg). The duration of licking and/or biting the injected area was counted 0-5 min (phase I) and 15-30 min (phase II) post-injection.
Spinal nerve ligation (SNL)-induced thermal hyperalgesia and mechanical allodynia in rats
Neuropathic pain was induced by SNL at spinal level L5 in rats (180-220 g) anesthetized with ketamine (100 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.). SNL was performed as described in detail elsewhere (Kim and Chung, 1992) . Sham animals, subjected to all of the same procedures as the SNL group with the exception of the nerve ligation step, were used as controls (SHAM group). Thermal hyperalgesia was evaluated by measuring the withdrawal reaction time in response to radiant heat (model 37370, Ugo Basile, Milan, Italy) applied to the plantar surface of hind paw (Sudo et al., 2015) . Mechanical allodynia was assessed with electronic von Frey (Analgesymeter Digital Device, model EFF301 Insight, São Paulo, Brazil) (Sudo et al., 2015) . The Von Frey stimuli were applied to the hind paw with a 120-g cut-off.
Thermal hyperalgesia and mechanical allodynia were assessed 7 days after SNL. After assessment of hyperalgesia and allodynia, the animals were treated with vehicle, clonidine (0.4 mg/kg), or PT-31 (1, 5, and 10 mg/kg) by gavage daily for 7 days After receiving PT-31 for 7 days (10 mg/kg/d, p.o.), rats were given a single i.p. injection of one of the following potentially interacting drugs (n = 4/group): yohimbine (5 mg/kg), an α 2 adrenoceptor antagonist (Jorum, 1988) , atropine (2 mg/kg), a muscarinic cholinergic receptor antagonist (Riedel et al., 2015) ; L-NAME (30 mg/kg), a nitric oxide synthase (NOS) inhibitor (Talbot et al., 2012) or naloxone (2 mg/ kg), an opioid receptor antagonist (Paranos et al., 2013) . Paw withdrawal latency was evaluated 0, 15 and 30 min after the i.p. drug administration, and then every 30 min thereafter for 2 h. The maximal reversal effect was considered in the analysis.
Motor skill and activity tests
Spontaneous motor activity of male Wistar rats (180-220 g) were observed using open field apparatus of 45 cm × 45 cm (LE8811; Letica, Barcelona, Spain), in which 16 infrared photocells were positioned every 2.5 cm on each side to create several invisible squares. Animals were placed in the center of the field and total locomotor activity was defined as the number of interruptions of the beams recorded in a computer during 60 min after oral administration of either vehicle, clonidine (0.4 mg/kg,), or PT-31 (10, 50 and 100 mg/kg). The data showed as number of movements per min.
In mice, motor skills were assessed with the rotarod test (Insight Equipamentos, São Paulo, SP, Brasil). The rotarod was turned at a speed of 8 rotations per minute during a 3 min observation period before and 30 min after oral administration of vehicle, clonidine (0.4 mg/kg), or PT-31 (10, 50 and 100 mg/kg). For each group, time spent on the rotarod without falling off 30 min post treatment and at various time points after oral administration (30, 60 and 120 min) were compared evaluated.
Blood pressure and electrocardiogram recordings
Male Wistar rats (180-220 g) were anesthetized by inhalation of 3% isoflurane (Cristália Produtos Químicos e Farmacêuticos Ltda, São Paulo, SP, Brazil) and a catheter (PE50) filled with heparin (50 IU/ml) in saline was placed into the right carotid artery for measurement of arterial blood pressure (BP) using a calibrated pressure transducer (MLT884, ADInstruments, Sydney, Australia). A pair of external electrodes was placed on the animal's chest to record the electrocardiogram (EKG). Additionally, a catheter was placed in a jugular vein of each animal for in bolus injection of PT-31 (10 mg/kg) or clonidine (0.4 mg/ kg) or vehicle. Both BP and EKG were recorded (PowerLab 7.0, ADInstruments, Sydney, Australia) continuously before and during administration of the substances. The hemodynamic data were measured when the maximum effect was observed.
Non-invasive BP was also performed in Wistar rats (180-220 g) using tail-cuff plethysmography (Letica model LE 5001, Cornella, Barcelona, Spain). Animals were treated p.o. daily for 10 days with either PT-31 (10 mg/kg), or clonidine (0.4 mg/kg), or vehicle. BP was measured before and 1, 7, and 10 days of treatment.
Statistical analysis
Results are reported as means ± standard errors of the mean (S.E.M.) The results of the hot plate, formalin, and rotarod experiments were subjected to one-way analyses of variance (ANOVA) followed by Newman-Keuls test. The thermal hyperalgesia and mechanical allodynia assessments were subjected two-way analysis of variance (ANOVA) followed by a post-hoc Dunnett's test. Locomotor and noninvasive BP test results were subjected to one-way ANOVA followed by Dunnet's multiple comparison test. Hemodynamic data were analyzed with paired Student's t-tests. The GraphPad Prism 5.0 program (GraphPad software Incorporated, San Diego, USA) was used for statistical analysis and graph production. Differences were considered significant at P < 0.05.
Results
Hot plate induced acute pain
PT-31 (10, 50, and 100 mg/kg p.o.) increased %MPE dose dependently (29.9 ± 6.7, 43.3 ± 12.0, and 73.4 ± 8.6%, respectively). The % MPE induced by clonidine (0.4 mg/kg) and morphine (10 mg/kg) were 71.9 ± 7.4 and 67.3 ± 7.6%, respectively; these values differed significantly from the %MPE value obtained for the 10 mg/kg PT-31 group, but not from those obtained for the 50 mg/kg and 100 mg/kg PT-31 groups (Fig. 1B) .
Formalin-induced nociception
The licking, scratching, or biting times (reactivity) observed in the phase I and phase II of the intraplantar formalin injection reaction were 51.5 ± 5.5 s and 197.6 ± 14.5 s, respectively. Reactivity during the phase I was not affected by oral administration of low-dose PT-31 (10 mg/kg) or acetylsalicylic acid (ASA, 150 mg/kg), but was reduced by the two higher doses of PT-31 (50 mg/kg and 100 mg/kg) to 27.2 ± 3.1 s and 13.4 ± 2.6 s, respectively, as well as by clonidine (0.4 mg/kg) to 2.3 ± 1.0 s (P < 0.05 vs. vehicle). Reactivity during the phase II was reduced by ASA and clonidine to 102.8 ± 17.2 s and 0.5 ± 0.3 s, respectively, (P < 0.05 vs. vehicle) and by PT-31 at all three doses (10 mg/kg, 71.3 ± 10.2; 50 mg/kg, 23.9 ± 10.3; and 100 mg/kg, 9.4 ± 3.9 s; all P < 0.05 vs. vehicle or ASA) (Fig. 1C) .
SNL-induced hyperalgesia and allodynia signals
PT-31 (1, 5, and 10 mg/kg, p.o.) reduced thermal hyperalgesia ( Fig. 2A ) and mechanical allodynia (Fig. 2B) in SNL rats in a dose-dependent manner. The thermal withdrawal latency was reduced 7 d after the SNL surgery P < 0.05 vs. pre-SNL in all groups except for the SHAM group. The PT-31 treatments had no effect on withdrawal latency or threshold in SHAM animals. Compared with the clonidine group (0.4 mg/kg, p.o.), the high-dose PT-31 group (10 mg/kg, p.o.) showed a greater reversal of thermal hyperalgesia (Fig. 3A) and mechanical allodynia (Fig. 3B ) (both P < 0.05).
Analgesic mechanism of PT-31 on SNL
All tested antagonists reduced the antihyperalgesic effect of PT-31 treatment (10 mg/kg/d). As shown in Fig. 4 , yohimbine, atropine, L-NAME, and naloxone decreased paw withdrawal latency from 14.3 ± 0.6 s to 7.3 ± 0.3 s, from 14.6 ± 0.6 s to 9.8 ± 0.6 s, from 13.5 ± 0.5 s to 10.3 ± 0.5 s, and 14.4 ± 0.5 s to 10.1 ± 0.4 s, respectively (all P < 0.05).
Motor skill and activity tests
In open field testing performed with single oral administration either of vehicle, or clonidine (0.4 mg/kg), or PT-31 (10 mg/kg, 50 mg/ kg, and 100 mg/kg), rats received vehicle exhibited 155.3 ± 29.5 movements/min. Relative to that of the vehicle group, activity was reduced in the clonidine group (54.6 ± 8.6 movements/min, P < 0.05)) (Fig. 5A) . No significant difference in motor activity was noted after PT-31 administration (respective dose responses: 117.5 ± 6.4, 123.3 ± 11.6, and 96.7 ± 18.2 movements/min) (Fig. 5A ). In the rotarod test, administration of vehicle (p.o.), PT-31 (10 mg/kg, 50 mg/kg, and 100 mg/kg, p.o.), or clonidine (0.4 mg/kg p.o.) did not change the amount of time mice were able to stay on the rotating rod (all P < 0.05 vs. pre-treatment) (Fig. 5B ).
Hemodynamics measurement
Hemodynamic changes were evaluated after intravenous injection of a bolus of vehicle, clonidine (0.4 mg/kg), or PT-31 (10 mg/kg). The lowest measurement of the hemodynamics parameters was presented in the results. Neither DMSO nor PT-31 affected any of the assessed hemodynamic parameters. However, systolic, diastolic, and mean BP were reduced (all P < 0.05) from 129.2 ± 5.9 mmHg to 44.7 ± 16.0 mmHg, from 88.2 ± 3.4 mmHg to 29.0 ± 10.4 mmHg, and from Fig. 2 . Antinociceptive effect of PT-31 (1, 5 and 10 mg/kg p.o.) on thermal hyperalgesia (A) and mechanical allodynia (B) induced by L5 level spinal nerve ligation (SNL) in rats. All compounds were administered once a day by gavage during 7 days as marked. Each point represents the mean ± S.E.M. (n = 6). *P < 0.05 vs day 0; # P < 0.05 vs day 7. Fig. 3 . Antinociceptive effect of PT-31 (10 mg/kg p.o.) and clonidine (0.4 mg/kg p.o.) on thermal hyperalgesia (A) and mechanical allodynia (B) induced by L5 level spinal nerve ligation (SNL) in rats. All compounds were administered once a day by gavage during 7 days as marked. The behavior tests were performed prior to the compounds administration. Each point represents the mean ± S.E.M. (n = 6). *P < 0.05 vs day 0; # P < 0.05 vs day 7.
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108.7 ± 4.6 mmHg to 36.6 ± 13.3 mmHg, respectively, after the clonidine injection (Fig. 6A-C) . In addition, clonidine reduced the rats' average heart rate from 334.4 ± 15.9 bpm to 198.6 ± 8.6 bpm (P < 0.05) (Fig. 6D ).
Orally administered vehicle or PT-31 (10 mg/kg) daily for 7 days did not have any significant effects on hemodynamic parameters in rats. However, similarly administered clonidine decreased the rats' systolic BP from 127.0 ± 3.7 mmHg to 96.7 ± 1.4 mmHg (P < 0.05) (Fig. 7A-C) .
Discussion
This study demonstrated that PT-31, a novel α 2A adrenergic receptor agonist reduces, in a dose-dependent manner, responses indicative of acute thermal pain (hot plate test), formalin-induced pain (both phases), and SNL-induced neuropathic pain in rodents. In addition, the analgesic effects of PT-31 are mediated mainly through activation of α 2A -adrenoceptors because PT-31-associated analgesia was abolished by yohimbine. Moreover, the present results provide evidence supporting the notion that PT-31 is an effective analgesic when taken orally, with the advantages over clonidine (Klimscha et al., 1995; Sakamoto et al., 2013) of not causing significant hemodynamic or behavioral side effects. The antinociceptive effect induced by PT-31 which was dissolved in DMSO/saline (1:1) was comparable to that of morphine and clonidine. The use of this formulation to dissolve PT-31 did not interfere with its activity because when another vehicle was used (hydroxymethylcellulose, benzylic alcohol, tween 80, edetate disodium), PT-31 (50 mg/kg) produced 43.3 ± 12.0% MPE which was not significantly different when using DMSO/saline. Since plasma concentration was not determined, the pharmacokinetic and pharmacodynamics relationship was not described
The phase I (early phase) and phase II (late phase) portions of the formalin test (Huang et al., 2016; Shannon et al., 2001 ) are associated with direct stimulation of peripheral afferents which are further activated by inflammatory mediators, respectively (McNamara et al., 2007) . The exact role of α 2 adrenoceptors in inflammatory processes is unclear. However, there is evidence of reductions in pro-inflammatory cytokines, macrophages, and lymphocytes in inflammatory exudate in the presence of clonidine, which may reflect the analgesic mechanism of clonidine. Given that the α 2 -adrenoceptor-mediated alleviation of hypersensitivity after peripheral nerve inflammation is associated with a reduction of pro-inflammatory cytokines in peripheral tissues (Romero-Sandoval and Eisenach, 2007) it is reasonable to suppose that PT-31's antinociceptive effects may be related to a similar suppression of inflammatory responses. The pathophysiology of neuropathic pain, which is characterized by allodynia and hyperalgesia (Woolf, 2011) , has yet to be understood. Furthermore, currently available pharmacotherapies used to treat these symptoms are often ineffective (Finnerup et al., 2007; Vranken, 2009; Wolkerstorfer et al., 2016) . Deleterious plasticity and dysfunction of neural tissue in the spinal cord following a primary insult affecting peripheral neurons may play an important role given that abnormal nerve activity underlies the spontaneous pain typical of neuropathic pain states. This abnormal activity comes from damaged peripheral nerves, at the level of nociceptors or neuromas, dorsal root ganglia, and the dorsal horn region of the spinal cord (Costigan et al., 2009; Jay and Barkin, 2014) . A plethora of changes in peripheral and central nervous systems after peripheral nerve injury, including alterations in sodium channel expression, microglial hyperactivation, and dendritic R.T. Sudo et al. European Journal of Pharmacology 815 (2017) 210-218 sprouting, can result in neural hyperexcitability (Rahman et al., 2008a (Rahman et al., , 2008b . Nerve injury is also associated with a variety of modifications in descending antinociceptive pathways, including changes in gene expression and regulation of α 2A-adrenoceptors in dorsal root ganglia and the spinal cord, although the findings for α 2A adrenoceptors have been contradictory (Cho et al., 1997; Stone et al., 1999) . The α 2 -adrenoceptors are distributed throughout the gray matter of the spinal cord (Funai et al., 2014; Kwiat and Basbaum, 1992) . Their density is particularly high in the surface lamina of the dorsal horn in both postsynaptic dorsal horn cells and primary afferent terminals (Roudet et al., 1994; Woolf, 2011) . Previous studies reported that PT-31 is capable of activating α 2A -adrenoceptor producing antinociceptive effect, which was reversed by yohimbine, a non-selective antagonist of α 2 adrenoceptor, and by BRL 44408, a selective α 2A -antagonist, but not blocked by ARC 239, an α 2B and α 2C antagonist (Sudo et al., 2010) . Activation of spinal α 2 -adrenoceptors results in both, inhibition of the neurotransmitter release from primary afferent terminals and blockage of spinal dorsal horn neurons excitation (Pertovaara, 2006; Roudet et al., 1994) .
The prototype α 2A adrenoceptor agonist clonidine is efficacious for alleviation of neuropathic pain symptoms (Sonohata et al., 2004) . Epidural clonidine is approved for treatment of neuropathic pain symptoms (Hayashida and Eisenach, 2010) , with the caution of the risk of side effects such as hypotension, bradycardia, and sedation (Klimscha et al., 1995; Sakamoto et al., 2013) . Previously, it was suggested that clonidine induce sedation through α 2-adrenoceptors which are located in fibers emerging from the locus coeruleus (Kostowski and Obersztyn, 1988; Nassif-Caudarella et al., 1986) . In the present study, when PT-31 was orally administered in rats, neither sedation nor alterations in locomotor activity were observed in an open field test, in contrast to clonidine that exhibited a sedative profile.
The noradrenergic system plays an important role in inhibitory descending pain control from the brainstem (Smith et al., 1995) . Activation of α 2 adrenoceptors by norepinephrine causes antinociception in numerous behavioral models of pain (Pertovaara, 2006) . This antinociception action is attributed to inhibition of presynaptic excitatory neurotransmitter release and postsynaptic hyperpolarization in the spinal cord (Hajhashemi et al., 2014; Kingery et al., 2002) . Many authors have demonstrated interactions of the analgesic mechanism of α 2 adrenoceptor agonists with cholinergic (Xu et al., 2000) , nitric oxide (NO) (Sonohata et al., 2004) and opioid (Zhang et al., 2011) actions, and our findings are consistent with the suggestion of such interactions.
Several lines of evidence support involvement of both spinal α 2 adrenergic and cholinergic receptors in the antinociceptive effects of clonidine in animals with hypersensitivity induced by SNL (Hayashida and Eisenach, 2010; Kang and Eisenach, 2003) . The α 2-adrenoceptors activate a presynaptic inhibition of excitatory neurotransmitter release related to decrease intracellular cAMP concentration via G i/o proteins. After nerve injury, α 2 -adrenoreceptor activation may enhance Ca 2+ -dependent acetylcholine release and this effect depends on a G s -proteincoupled mechanism (Bantel et al., 2005; Hayashida and Eisenach, 2010) . Peripheral nerve injury alters α 2 adrenoceptor function on spinal cholinergic terminals from an inhibitory one to a facilitator one. This change is important for the analgesia produced by drugs commonly used to treat neuropathic pain and further confirms the supposed interaction of spinal noradrenergic and cholinergic pathways. The present finding that atropine reduced the analgesic effect of PT-31 in SNL rats supports the notion that PT-31 induced analgesia is dependent, at least in part, upon the activation of cholinergic receptors. Peripheral nerve injury has been associated with the suppression of tonic noradrenergic activity in the spinal cord, an effect which impedes the antinociceptive response (Rahman et al., 2008a (Rahman et al., , 2008b Viisanen and Pertovaara, 2007) .
L-NAME, an inhibitor of NOS, attenuated PT-31-induced analgesia which indicates a putative adrenergic-nitric oxide interaction in pain modulation. Neuronal NOS is expressed by neurons of the spinal dorsal horn and production of nitric oxide increases the release of excitatory neurotransmitters (Garry et al., 2000) , an effect which would be expected to enhance pain neurotransmission. Although the role of nitric oxide itself in neuropathic pain is unclear (Xu et al., 2012) , the analgesic effect of intrathecal clonidine after nerve injury can be reversed by NOS inhibitors (Pan et al., 1999 ).
An interaction between opioid and α 2 adrenergic pathways in analgesia is well documented. A variety of studies have demonstrated that the analgesic effects of α 2 adrenoceptor agonists can be reversed by naloxone, whereas a synergistic interaction can been induced by coadministration of opioids and α 2-adrenoceptor agonists (Sudo et al., 2010) . Naloxone blocks the antinociceptive effects of clonidine via local effects on opioid receptors on noradrenergic terminals, where clonidine also modulates nociception transmission. Thus, naloxone inhibits clonidine analgesia through an interaction at the µ opioid receptor (Sierralta et al., 1996) .
A major concern regarding α 2-adrenoceptor induced analgesia is the possibility for serious side-effects, such as sedation (Jamadarkhana and Gopal, 2010; Torrance et al., 2013) , bradycardia and hypotension (Eisenach et al., 1996) . Clonidine stimulates presynaptic α 2 adrenoceptors, thereby decreasing noradrenaline release from both central and peripheral sympathetic nerve terminals. The analgesic effects of α 2-adrenoceptor activation involve actions at both spinal and supraspinal sites, including depression of thalamic transmission of corticopetal impulses as well as enhancement of descending inhibitory pathways to the dorsal horn. Supraspinally, the locus coeruleus has been implicated as a critical site for the sedative and analgesic actions of α 2-adrenoceptor activation by radioligand studies (Jamadarkhana and Gopal, 2010; Torrance et al., 2013) . Hence, our present finding of antinociceptive effects of PT-31 without any evidence of sedative, motor impairing, or hypotensive effects after a single intravenous injection or 7 days of oral administration suggests that PT-31 may provide with clonidine-like analgesia without clonidine-associated side effects.
Conclusion
The novel α 2 agonist PT-31 is a candidate for acute and chronic pain treatment. PT-31 has antinociceptive efficacy when administered orally and does not produce the central nervous system or hemodynamic side effects associated with other α 2-adrenoceptors agonists such as clonidine.
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